Objective:To discuss the influence of intensive lipid-lowering therapy by atorvastatin on blood lipid and serum von Wille-brand factor ( vWF) and thrombomodulin ( TM) levels of patients with unstable angina pectoris. Methods: Totally 88 cases of patients with unstable angina pectoris were selected and divided into the intensive group (n=44) and the routine group (n=44) at random. The patients in the two groups were given routine medical treatment, such as nitrates, bayaspirin,β-blocker, low molecular heparin and etc. The patients in the routine group were orally given atorvastatin 20mg, qd, while the patients in the intensive group were given atorvastatin 40mg, qd with the treatment course of 8 weeks. The changes in serum vWF and TM levels in the two groups before and after the medical treatment were observed, and the occurrence rates of cardiac ischemia related events and untoward effect during the medical treatment were compared as well. Results:After the 8-week medical treatment, the levels of TC, TG and LDL-C in the two groups were obviously declined and the levels of HDL-C were obviously increased than those before the treatment (P<0. 05 or P<0. 01), and the declining and increasing rates in the intensive group were much higher than those in the routine group (P<0. 05). The serum vWF and TM levels in the two groups were obviously declined than those before the treatment (P<0. 05 or P<0. 01), and the declining rates in the intensive group were much higher than those in the routine group (P<0. 05). The occurrence rates of cardiac ischemia related events in the inten-sive group during the medical treatment were much lower than those in the routine group (P<0. 05). Respectively 4 and 6 cases of unto-ward effect appeared in the routine group and the intensive group during the medial treatment with light symptom, and the difference showed no obvious statistical significance (P>0. 05). Conclusion:Atorvastatin intensive lipid-lowering has favorable curative effect and security in the treatment of unstable angina pectoris, which can reduce the occurrence rates of cardiac ischemia related events, and the mechanism is related to reducing blood lipid and serum vWF and TM levels and improving the function of vascular endothelial cells.